Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study

References

• Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1–39
   PubMedGoogle Scholar
• Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 2005;30:2484–90
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273–81
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7:583–91
   PubMed Web of Science ®Google Scholar
• Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliative Med 2004;18:177–83
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195–206
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832–9
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129–34
   Google Scholar
• Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55–64
   Google Scholar
• Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998;16:179–83
   PubMed Web of Science ®Google Scholar
• Miaskowski C, Cleary J, Burney R, et al. Guideline for the management of cancer pain in adults and children. APS Clinical Practice Guidelines Series, No. 3 ed. Glenview (IL): American Pain Society; 2005
   Google Scholar
• Darwish M, Kirby M, Robertson Jr P, et al. Comparative bioavailability of the novel fentanyl effervescent buccal tablet formulation: an open-label crossover study. Poster presented at the American Pain Society annual meeting, May 3–6, 2006, San Antonio, TX
   Google Scholar
• Portenoy R, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl effervescent buccal tablets for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805–11
   PubMed Web of Science ®Google Scholar
• ICH Expert Working Group. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). June 10, 1996
   Google Scholar
• Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983;17:197–210
   Google Scholar
• Fairbank JC, Pynsent PB. The Oswestry disability index. Spine 2000;25:2940–52
   PubMed Web of Science ®Google Scholar
• Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611–6
   PubMed Web of Science ®Google Scholar
• Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 2006;4:1–5
   Google Scholar
• Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005;44:1279–86
   PubMed Web of Science ®Google Scholar
• Darwish M, Tempero K, Kirby M, Thompson J. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 µg versus oral transmucosal fentanyl citrate 1600 µg and dose proportionality of FEBT 270 to 1300 µg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther 2006;28:715–2
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson Jr P, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers. Clin Ther 2006;28:707–14
   PubMed Web of Science ®Google Scholar
• Payne R, Coluzzi P, Hart L, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22:575–83
   PubMed Web of Science ®Google Scholar
• Hanks GW, Nugent M, Higgs CMB, Busch MA. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliative Med 2004;18:698–704
   PubMed Web of Science ®Google Scholar
• Collins SL, Faura CC, Moore RA, McQuay HJ. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998;16:388–402
   PubMed Web of Science ®Google Scholar
• Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005;29:S57–S66
   PubMed Web of Science ®Google Scholar
• Prommer E. Oxymorphone: a review. Support Care Cancer 2006;14:109–15
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy Jr JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain 2001;91:123–30
   PubMed Web of Science ®Google Scholar